Hamish Mykura, 59, from West Sussex, has seen his tumour disappear from scans. He was diagnosed with glioblastoma in August 2018 and was referred to the Royal Marsden for treatment, which included chemotherapy and radiotherapy, with surgery at St Georgeâs hospital. When the treatment stopped working and the cancer started to grow in August 2019, he joined the Ice-Cap trial. Twenty months on, Hamish has no visible cancer.
âThe emotional journey I have been on over the last few years has been dramatic and, considering the seriousness of my diagnosis, itâs astonishing that Iâm still here,â he said. âIn fact, a few months into the trial it felt like all hope had gone as it appeared my cancer had started growing again. However, surgery revealed the growth was actually inflammation caused by the drugs attacking the tumour â they were working. Ever since, Iâve been in a great position with scans indicating my cancer is stable.
Share this article
Share this article
PRINCETON, N.J., April 11, 2021 /PRNewswire/ Taiho Oncology, Inc. today announced efficacy and safety results from the Phase 2 FOENIX-CCA2 trial, a single-arm multicenter Phase 2 study evaluating futibatinib (TAS-120) in patients with intrahepatic cholangiocarcinoma (iCCA) harboring
FGFR2 gene rearrangements including gene fusions who have failed at least one line of therapy. The data were presented online as an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021 Week 1 Clinical Trials Plenary from 2:00 – 3:45 PM ET on April 11, 2021.
In the FOENIX-CCA2 trial, 103 patients with locally advanced or metastatic unresectable iCCA harboring
FGFR2 gene rearrangements including fusions who had received one or more prior lines of systemic therapy received futibatinib 20 mg once daily until disease progression or unacceptable toxicity. The study met its primary endpoint of a greater than 20% object
Share this article
Share this article
INDIANAPOLIS, April 11, 2021 /PRNewswire/ Eli Lilly and Company (NYSE: LLY) today announced for the first time data from the Phase 1/2 LIBRETTO-001 trial showing treatment with Retevmo
® (selpercatinib) demonstrated encouraging antitumor activity and safety across
RET fusion-positive advanced solid tumors beyond lung and thyroid cancers, including multiple treatment-refractory gastrointestinal (GI) malignancies. The data were presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, held virtually April 10-15, 2021. We are excited to broaden the body of evidence for Retevmo in
RET fusion-positive cancers beyond lung and thyroid tumors, said David Hyman, M.D., chief medical officer, oncology at Lilly. These encouraging outcomes, including in difficult-to-treat GI malignancies, support a growing body of evidence that
Early findings show new drug could be ‘game-changing’ for brain cancer treatment Sarah Boseley
Two people with advanced brain cancer of the sort that led to the death of the MP Tessa Jowell have responded well in a small trial to an experimental combination of chemo and immunotherapy drugs. In one case, the life-threatening tumour seems to have disappeared.
Doctors at the Institute of Cancer Research and the Royal Marsden hospital in London cautioned that this was very early research but said it was unusual to have such a good response in patients in an early trial.
Ten patients were enrolled in the phase I trial called Ice-Cap. They had advanced glioblastoma, a tumour in the brain similar to that which also killed US president Joe Biden’s son, Beau.
MD Anderson researchers highlight advances in clinical studies at AACR Annual Meeting 2021 miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.